

## PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/208247>

Please be advised that this information was generated on 2020-09-10 and may be subject to change.

# Diagnostic accuracy of office blood pressure compared to home blood pressure in patients with mild cognitive impairment and dementia

European Journal of Cardiovascular Nursing  
2019, Vol. 18(7) 637–642  
© The European Society of Cardiology 2019



Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/1474515119855822  
journals.sagepub.com/home/cnu



Rianne AA de Heus<sup>1,2</sup>, Maxime V Tumelaire<sup>1,2</sup>,  
Marcel GM Olde Rikkert<sup>1,2</sup> and Jurgen AHR Claassen<sup>1,2</sup>

## Abstract

**Background:** Hypertension and cognitive impairment often coexist in older people. Office blood pressure measurement is a poor indicator for diagnosing hypertension in the general population. However, its diagnostic accuracy has not been substantially studied in patients with cognitive impairment.

**Aim:** The aim of this study was to determine the proportion of misdiagnosis of hypertension in patients with mild cognitive impairment and dementia compared to no cognitive impairment, by comparing office blood pressure measurement with home blood pressure measurement.

**Methods:** A cross-sectional study including consecutive patients visiting a memory clinic between 2014 and 2017. Home blood pressure was measured for one week according to the European guidelines. Office blood pressure was assessed during routine clinical practice. Using guideline definitions for normal blood pressure and hypertension, we investigated the proportion of disagreement between office blood pressure measurement and home blood pressure measurement. Univariable and multivariable logistic regression compared disagreement in diagnosis between patients with dementia, mild cognitive impairment and no cognitive impairment.

**Results:** Of 213 patients (aged  $73.4 \pm 9.0$  years, 42% women) 82 had dementia, 65 had mild cognitive impairment and 66 had no cognitive impairment. Mean office blood pressure was  $156/84 \pm 23/11$  mmHg and mean home blood pressure was  $139/79 \pm 16/10$  mmHg. In 31% of patients, there was disagreement in hypertension diagnosis. This proportion was higher for mild cognitive impairment (38.5%) and dementia (35.4%) compared to no cognitive impairment (18.2%), with adjusted odds ratios of 3.7 (95% confidence interval 1.5–9.0),  $P=0.005$  for mild cognitive impairment and 3.4 (1.3–8.6),  $P=0.011$  for dementia.

**Conclusions:** In memory clinic patients with dementia and mild cognitive impairment, the diagnostic accuracy of office blood pressure measurement is lower compared to patients without cognitive impairment. To avoid the risk of making improper treatment decisions in this vulnerable group, a diagnosis of hypertension should be based on home blood pressure measurement, not office blood pressure measurement.

## Keywords

Dementia, mild cognitive impairment, blood pressure, hypertension

Date received: 6 February 2019; accepted: 17 May 2019

## Introduction

Hypertension is the most prevalent treatable risk factor for cardiovascular diseases, affecting  $\pm 75\%$  of people aged over 70 years.<sup>1,2</sup> There is controversy regarding hypertension management in older people with cognitive impairment,<sup>3</sup> despite these morbidities often coexisting in this group.<sup>4</sup> This group has been excluded from randomised

<sup>1</sup>Department of Geriatric Medicine, Radboud University Medical Center, The Netherlands

<sup>2</sup>Radboudumc Alzheimer Center, Radboud University Medical Center, The Netherlands

### Corresponding author:

Jurgen Claassen, Department of Geriatric Medicine, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, 925, The Netherlands.

Email: Jurgen.Claassen@radboudumc.nl

controlled trials estimating the benefit-to-risk ratio of anti-hypertensive treatment. Based on observational evidence, it is postulated that people with cognitive impairment are more prone to side-effects of treatment (such as hypotension and falls) and might even show a more rapid cognitive decline with hypertension treatment.<sup>5, 6</sup> Considering this ongoing discussion, the current clinical advice is to assess blood pressure (BP) carefully and accurately in this group,<sup>7</sup> because treatment decisions based on an incorrect diagnosis of hypertension may expose people with cognitive impairment to greater risks than older people with normal cognitive function.

It has generally been acknowledged that the accuracy of an office blood pressure measurement (OBPM) is low and hence out-of-office measurements are now recommended by guidelines.<sup>8, 9</sup> Ambulatory blood pressure monitoring over 24 hours (ABPM) has been accepted internationally as the gold standard for hypertension diagnosis,<sup>10</sup> but can be experienced as invasive,<sup>11</sup> and may result in lifestyle disruption, especially in people with cognitive impairment, which reduces its representability for daily life. In addition, it comes with considerable costs. Home blood pressure monitoring (HBPM) has been shown to be a feasible and reliable alternative for ABPM in several populations,<sup>12</sup> including patients with dementia.<sup>13</sup> Not unexpectedly, the majority of dementia patients also indicated that they preferred HBPM over ABPM.

In a general older population (mean age 70 years) the prevalence of a misdiagnosis of hypertension with OBPM, compared with HBPM, was 22%.<sup>14</sup> This percentage consisted of false positives (i.e. white-coat hypertension, 13%) and false negatives (i.e. masked hypertension, 9%). It is unknown whether these findings can be extrapolated to a population of older people with cognitive impairment. Therefore, the aim of this study was to investigate the proportion of misdiagnosis of hypertension with OBPM, when compared to HBPM, in older people with mild cognitive impairment (MCI) and dementia.

## Methods

### Participants

This cross-sectional study included consecutive patients referred to the memory clinic at a university teaching hospital between 2014 and 2017. Patients who agreed to perform HBPM were eligible for this study. The study was approved by the medical ethics committee and used an opt-out consent approach for the use of medical records. The investigation conforms with the principles outlined in the Declaration of Helsinki.

Of 1159 referred patients, 261 agreed to perform HBPM and did not opt out. Patients who received HBPM had higher systolic office blood pressure (SBP;  $155.9 \pm 22.8$  vs.

$150.9 \pm 23.4$  mmHg,  $P=0.005$ ), were less often women (40.7% vs. 53.0%,  $P=0.001$ ), and less frequently had a diagnosis of dementia (39.5% vs. 58.8%,  $P<0.001$ ). For details see Supplementary Table 1 and Supplementary Figure 1.

### Clinical measurements

Clinical information was collected during a comprehensive geriatric assessment by a geriatric medicine registrar. This included information on sociodemographics, psychosocial abilities, functional abilities, cardiovascular history, medication use and cognitive screening. Cardiovascular history was marked as present if one of the following conditions was identified in the medical history: chronic heart failure, coronary heart disease, arrhythmia, cerebrovascular disease, or peripheral artery disease. Cognitive screening included the Mini-Mental State Examination (MMSE; 01/2014–04/2016) or the Montreal cognitive assessment (MoCA; 05/2016–12/2017).<sup>15, 16</sup> Functional abilities were assessed with the Barthel index for activities of daily living and the Lawton–Brody scale for instrumental activities of daily living.<sup>17, 18</sup> Supine OBPM was taken using a manual sphygmomanometer according to standard clinical practice. Cognitive diagnoses were established in a multidisciplinary meeting with geriatricians and neuropsychologists, based on all information from the geriatric assessment and when necessary after additional diagnostic testing (i.e. neuropsychological testing or neuro-imaging), using international diagnostic criteria.<sup>19, 20</sup> Based on this assessment we categorised patients into three cognitive groups: dementia (any type), MCI and cognitively normal (CN; i.e. subjective cognitive complaints).

### Home BP measurement

HBPM involved a validated, memory equipped, automatic oscillometric device (Microlife WatchBP Home, Microlife, Heerbrugg, Switzerland), following recommendations of the European Society of Hypertension.<sup>21, 22</sup> This comprised duplicate measurements in the morning (06:00–10:00 hours) and evening (17:00–21:00 hours) for 7 consecutive days, resulting in a maximum of 28 measurements. As recommended, measurements for day 1 were discarded and mean BP was not calculated if patients performed fewer than 12 measurements.<sup>22</sup> Patients and (when applicable) their caregiver received a demonstration and written instructions on how to measure home BP. Patients were instructed to sit in a straight chair with the arm supported by a table for at least 5 minutes before starting a measurement.

### Outcomes

The main outcome of interest was the presence of disagreement in hypertension diagnosis between OBPM and

HBPM. Disagreement in diagnosis was defined as either hypertension on OBPM, but normal HBPM (i.e. white-coat hypertension) or as normal OBPM, but hypertension on HBPM (i.e. masked hypertension). The cut-off point for hypertension on OBPM was SBP  $\geq$ 140 mmHg and/or diastolic blood pressure (DBP)  $\geq$ 90 mmHg. The cut-off point for hypertension on HBPM was SBP  $\geq$ 135 mmHg and/or DBP  $\geq$ 85 mmHg.<sup>8</sup> To explore these results further, the presence of white-coat hypertension and masked hypertension were also analysed separately and an analysis with only morning or evening HBPM was performed.

### Statistical analysis

Continuous and categorical variables were presented as mean (SD) or median (interquartile range) and % (*n*), respectively. Descriptive variables were compared between patients with dementia, MCI and CN with analysis of variance, chi-squared test or the Kruskal–Wallis test, as appropriate.

Univariable and multivariable logistic regression models were used to examine the association between disagreement in hypertension diagnosis and cognitive groups. The group of CN patients was used as a reference. In the multivariable model we adjusted for age, sex, level of education (low/medium/high),<sup>23</sup> cardiovascular history (present/absent), use of BP-lowering medication (yes/no) and living situation (alone or with spouse). Unadjusted and adjusted odds ratios with 95% confidence intervals were reported. All analyses were performed using IBM SPSS Statistics 25.0 (SPSS, Inc., Chicago, IL, USA). In order to detect a difference in the proportion of misdiagnosis of 18%, with a power of 80% and alpha set at 0.05, a sample size of 209 patients was required. For details of the sample size calculation see the Supplementary material.

### Results

Ninety per cent (236/261) of the patients who agreed to perform HBPM reached the minimum threshold of 12 measurements. There were no relevant differences in characteristics between those with successful and unsuccessful HBPM, as described in Supplementary Table 2. For 9.7% (23/236) of the patients OBPM was missing in the medical record, leading to a final study sample of 213.

Table 1 shows the characteristics of the final study sample. More than two-third (69%) of the patients in the study had a diagnosis of dementia or MCI. Patients with dementia or MCI were significantly older compared to CN patients. Mean home BP was on average  $-16.8/-5.0$  mmHg lower than office BP. This difference was similar across the groups.

In 31% of patients, there was disagreement in hypertension diagnosis between OBPM and HBPM. This proportion was 35.4% for dementia patients, 38.5% for MCI patients and 18.2% for CN patients (Figure 1). The unadjusted and adjusted odds ratios and 95% confidence intervals are presented in Table 2. Compared to the CN patients, the adjusted odds ratios of disagreement in diagnosis were 3.4 (1.3–8.6) for dementia and 3.7 (1.5–9.0) for MCI.

In additional analyses we analysed the two types of disagreement in hypertension diagnosis separately. We observed a similar pattern for white-coat hypertension, but not for masked hypertension (Table 2). When morning and evening HBPM were analysed separately, similar results were obtained (Supplementary Tables 3 and 4).

### Discussion

We investigated the diagnostic accuracy of OBPM compared to HBPM in a memory clinic population. Using recommended cut-offs for hypertension diagnosis, 31% of patients showed disagreement between OBPM and HBPM. The proportion of disagreement was doubled in patients with dementia and MCI compared to CN patients. Even after adjusting for several demographic factors, we found that having dementia or MCI was associated with an increased risk of incorrect hypertension diagnosis. This was mainly driven by a higher prevalence of white-coat hypertension in dementia and MCI and in a smaller extent to a higher prevalence of masked hypertension in dementia.

Previous research showed that the proportion of disagreement between OBPM and HBPM in a cohort of treated hypertensive patients (mean age 70 years) was 22%,<sup>14</sup> which is comparable to our observation in the CN group. Our results now indicate that in older people with cognitive impairment, OBPM is even less accurate. Given previous observations that HBPM is well tolerated and reliable in patients with dementia,<sup>13</sup> this advocates for the use of HBPM before any decisions regarding BP management are made.

Several concepts can be proposed to explain this observation. First, patients with MCI or dementia visiting the clinic might experience more stress or anxiety, resulting in a higher proportion of white-coat hypertension.<sup>24</sup> More speculatively, the seemingly higher prevalence of masked hypertension in dementia patients might be an expression of reduced compliance to antihypertensive treatment in daily life,<sup>25</sup> while patients are reminded to take their medication on the morning of a planned doctor's visit. Of note here is that 10/12 dementia patients with masked hypertension were indeed prescribed antihypertensive medication. Finally, increased BP variability has been suggested to be involved in the pathophysiology of dementia and can result in a less reliable measurement with only one

**Table 1.** Descriptive characteristics of memory clinic patients by cognitive group.

	Total sample (n=213)	Dementia (n=82)	MCI (n=65)	CN (n=66)	P value
<b>Characteristics</b>					
Age, years	73.4 (9.0)	77.3 (7.4)	74.4 (8.0)	67.5 (8.8)	<0.001
Sex, female, % (n)	41.8 (89)	45.1 (37)	43.1 (28)	36.4 (24)	0.544
MMSE score, median (IQR) <sup>a</sup>	23 (26–28)	23 (20–25)	26 (24–28)	28 (26–29)	<0.001
MoCA score, median (IQR) <sup>a</sup>	21 (17–24)	16.5 (11–21)	22 (19–24)	25 (21–28)	<0.001
ADL, median (IQR) <sup>b</sup>	20 (19–20)	20 (18–20)	20 (19–20)	20 (19–20)	0.042
IADL, median (IQR) <sup>c</sup>	6.0 (3.5–8.0)	4.0 (2.0–6.0)	7.0 (5.5–8.0)	8.0 (4.3–8.)	<0.001
Number of drugs, median (IQR)	4 (1–7)	4 (2–7)	4 (1–7)	5 (1–8)	0.872
Use of BP-lowering drug, % (n)	58.2 (124)	61.0 (50)	56.9 (37)	56.1 (37)	0.808
History of CVD, % (n)	43.2 (92)	46.3 (38)	43.1 (28)	39.4 (26)	0.698
Education level, % (n) <sup>d</sup>					0.149
Low	15.5 (33)	22.0 (18)	12.3 (8)	10.6 (7)	
Medium	50.2 (107)	52.4 (43)	49.2 (32)	48.5 (32)	
High	34.3 (73)	25.6 (21)	38.5 (25)	40.9 (27)	
Living with spouse, % (n)	73.7 (157)	74.4 (61)	76.9 (50)	69.7 (46)	0.633
<b>Blood pressure measurements</b>					
Office systolic BP, mmHg	156.1 (23.3)	157.5 (26.9)	156.6 (18.8)	154.0 (22.6)	0.650
Office diastolic BP, mmHg	83.9 (10.6)	82.6 (10.2)	83.1 (9.0)	86.4 (12.1)	0.075
Office heart rate, bpm <sup>e</sup>	67.8 (11.5)	68.6 (12.2)	68.8 (11.7)	65.9 (10.2)	0.313
Home systolic BP, mmHg	139.3 (16.2)	140.7 (16.4)	138.1 (16.4)	138.8 (15.9)	0.596
Home diastolic BP, mmHg	78.9 (9.5)	77.0 (9.2)	78.0 (9.5)	82.1 (9.1)	0.003
Home heart rate, bpm	69.2 (9.8)	69.3 (10.6)	69.6 (9.8)	68.6 (8.8)	0.819
Home office systolic BP, mmHg	-16.8 (21.1)	-16.8 (24.4)	-18.5 (20.8)	-15.2 (17.9)	0.685
Home office diastolic BP, mmHg	-5.0 (10.4)	-5.6 (10.4)	-5.1 (9.6)	-4.3 (11.2)	0.734
<b>Study outcomes</b>					
Disagreement in diagnosis, % (n)	31.0 (66)	35.4 (29)	38.5 (25)	18.2 (12)	
White-coat hypertension, % (n)	22.5 (48)	20.7 (17)	33.8 (22)	13.6 (9)	
Masked hypertension, % (n)	8.5 (18)	14.6 (12)	4.6 (3)	4.5 (3)	

<sup>a</sup>Ranges from 0 to 30, higher score indicates better cognitive performance. MMSE was used at the memory clinic between 01/2014 and 04/2014 and is available for 156 patients, while MoCA was used between 05/2016 and 12/2017 and is available for 52 patients.

<sup>b</sup>Ranges from 0 to 20, higher score indicate less ADL dependency. Score is available for 171 patients.

<sup>c</sup>Ranges from 0 to 8, higher score indicates less IADL dependency. Score is available for 169 patients.

<sup>d</sup>Classified according to a previous reported system [27].

<sup>e</sup>Available for 176 patients.

Results are presented as mean (standard deviation) unless otherwise noted. P value derived from analysis of variance, chi-squared test or Kruskal–Wallis test, as appropriate.

MCI: mild cognitive impairment; CN: cognitively normal; IQR: interquartile range; MMSE: Mini-Mental State Examination; MoCA: Montreal cognitive assessment; ADL: activities of daily living; IADL: instrumental activities of daily living; BP: blood pressure; CVD: cardiovascular disease.

observation, as is the case with OBPM.<sup>26</sup> In these interpretations we refer to HBPM as the reference standard, which is supported by ample evidence. However, it cannot be completely ruled out that HBPM is responsible for the observed disagreement between groups.

### Strengths and limitations

In this study, HBPM was measured according to the European guidelines using a validated device equipped with a memory function and set at fixed time windows. Measurement of OBPM was part of the routine clinical practice, and as a result was assessed by different physicians, which could have introduced observer bias.<sup>27</sup>

Nevertheless, it does represent normal clinical practice for OBPM. Also, OBPM was performed manually and HBPM was automated. While it would have been a good extension of this work also to study automated OBPM, it was recently shown that only unattended automated OBPM is comparable to HBPM and attended automated OBPM is as discrepant from HBPM as manual OBPM.<sup>28</sup>


Patients who agreed to perform HBPM were biased towards cognitively healthier patients with a higher OBPM. Still, the studied sample included a large diversity of age, cognitive function and BP. We compared our dementia and MCI patients to memory clinic patients without objectively diagnosed cognitive impairment and not to a group of healthy controls. The generalisability of this

**Table 2.** Univariable and multivariable logistic regression models.

	Disagreement in HT diagnosis		White-coat hypertension		Masked hypertension	
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Unadjusted						
CN	1.0 (ref)	–	1.0 (ref)	–	1.0 (ref)	–
MCI	2.8 (1.3–6.3)	0.011	3.2 (1.4–7.7)	0.008	1.0 (0.2–5.3)	0.985
Dementia	2.5 (1.2–5.3)	0.022	1.7 (0.7–4.0)	0.263	3.6 (1.0–13.3)	0.055
Adjusted						
CN	1.0 (ref)	–	1.0 (ref)	–	1.0 (ref)	–
MCI	3.7 (1.5–9.0)	0.005	5.1 (1.9–13.9)	0.001	0.7 (0.1–4.4)	0.747
Dementia	3.4 (1.3–8.6)	0.011	2.9 (1.0–8.5)	0.047	2.3 (0.5–10.6)	0.295

The adjusted model is corrected for age, sex, educational level, use of blood pressure-lowering medication, history of cardiovascular history and living situation.

HT: hypertension; OR: odds ratio; CI: confidence interval; CN: cognitively normal; MCI: mild cognitive impairment.



**Figure 1.** Proportion of disagreement in hypertension diagnosis by cognitive group, split in proportion due to white-coat hypertension and due to masked hypertension.

Disagreement in diagnosis was defined as high office blood pressure (OBP), but a normal home blood pressure (HBP) (white-coat hypertension) or as normal OBP, but high HBP (masked hypertension) with cut-off points for high OBP of systolic blood pressure (SBP)  $\geq 140$  mmHg and/or diastolic blood pressure (DBP)  $\geq 90$  mmHg and cut-off points for high HBP of SBP  $\geq 135$  mmHg and/or DBP  $\geq 85$  mmHg. CN: cognitively normal; MCI: mild cognitive impairment; HT: hypertension.

group has been questioned,<sup>29</sup> although it was recently shown that cognitive function in this group is mostly stable in the long term.<sup>30</sup> In addition, the proportion of misdiagnosis (18.5%) in our CN group compares well with the 22% observed in the general population of older people. As the study had a cross-sectional study design, we were not able to study the prognostic value of HBPM compared to OBPM. Finally, despite giving oral and written instructions not to measure within one hour after food or drug intake and to have 5 minutes rest before measuring, we cannot ensure adherence to these instructions.

## Conclusion

We found that in memory clinic patients with dementia and MCI the proportion of disagreement between OBPM and HBPM was high, indicating a lower diagnostic accuracy of OBPM compared to older memory clinic patients with no cognitive impairment. For clinical practice, this advocates the use of HBPM in this group before any decisions regarding BP management are made. In view of the new guideline advice for lower thresholds for treatment of hypertension in older patients, a diagnosis of hypertension should be based on reliable BP measurements. For one-third of patients with MCI and dementia, OBPM leads to an inaccurate diagnosis. In these patients, the benefit-to-risk ratio of hypertension treatment remains uncertain and an individualised approach based on accurate BP measurements is therefore highly desirable.

## Acknowledgements

The authors would like to thank all study participants and their caregivers for their time and effort. They also thank the secretary and all involved residents of the Radboudumc Alzheimer Center for their support with the recruitment and are grateful to Jeannette Bronk-van Hoorn, Anne Lieke Meendering, Lotte van den Ingh, Faize Önen and Emma Peters for their role in data capture.

## Declaration of conflicting interests

The authors declare that there is no conflict of interest.

## Funding

The authors disclosed receipt of the following financial support for the research, authorship, and publication of this article: this work was supported by the Dutch Alzheimer Society (grant number WE.09-2015-03).

## Supplementary material

Supplementary material for this article is available online.

## References

1. Lawes CM, Vander Hoorn S and Rodgers A. Global burden of blood-pressure-related disease, 2001. *Lancet* 2008; 371: 1513–1518.
2. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. *Lancet* 2005; 365: 217–223.
3. van der Wardt V, Logan P, Conroy S, et al. Antihypertensive treatment in people with dementia. *J Am Med Directors Assoc* 2014; 15: 620–629.
4. Welsh TJ, Gladman JR and Gordon AL. The treatment of hypertension in people with dementia: a systematic review of observational studies. *BMC Geriatrics* 2014; 14: 19.
5. Mossello E, Pieraccioni M, Nesti N, et al. Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs. *JAMA Intern Med* 2015; 175: 578–585.
6. Bellew KM, Pigeon JG, Stang PE, et al. Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. *Alzheimer Dis Assoc Disord* 2004; 18: 208–213.
7. Harrison JK, Van Der Wardt V, Conroy SP, et al. New horizons: the management of hypertension in people with dementia. *Age Ageing* 2016; 45: 740–746.
8. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J* 2018; 39: 3021–3104.
9. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension (Dallas, Tex: 1979)* 2017; 11: e111–e133.
10. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. *J Hypertens* 2013; 31: 1731–1768.
11. Beltman FW, Heesen WF, Smit AJ, et al. Acceptance and side effects of ambulatory blood pressure monitoring: evaluation of a new technology. *J Human Hypertens* 1996; 10 (Suppl. 3): S39–S42.
12. Ward AM, Takahashi O, Stevens R, et al. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. *J Hypertens* 2012; 30: 449–456.
13. Plichart M, Seux ML, Caillard L, et al. Home blood pressure measurement in elderly patients with cognitive impairment: comparison of agreement between relative-measured blood pressure and automated blood pressure measurement. *Blood Pressure Monit* 2013; 18: 208–214.
14. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. *JAMA* 2004; 291: 1342–1349.
15. Folstein MF, Folstein SE and McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *J Psych Res* 1975; 12: 189–198.
16. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; 53: 695–699.
17. Lawton MP and Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *The Gerontologist* 1969; 9: 179–186.
18. Mahoney FI and Barthel DW. Functional evaluation: the Barthel Index. *Maryland State Med J* 1965; 14: 61–65.
19. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med* 2004; 256: 183–194.
20. American Psychiatric Association. *Diagnostic and Statistical Manual Of Mental Disorders (4th ed., text rev.)*. Washington, DC: APA, 2000.
21. Stergiou GS, Giovas PP, Gkinos CP, et al. Validation of the Microlife WatchBP home device for self home blood pressure measurement according to the international protocol. *Blood Pressure Monit* 2007; 12: 185–188.
22. Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. *J Hypertens* 2008; 26: 1505–1526.
23. Van der Elst W, van Boxtel MP, van Breukelen GJ, et al. Rey’s verbal learning test: normative data for 1855 healthy participants aged 24–81 years and the influence of age, sex, education, and mode of presentation. *J Int Neuropsych Soc: JINS* 2005; 11: 290–302.
24. Bo M, Massaia M, Merlo C, et al. White-coat effect among older patients with suspected cognitive impairment: prevalence and clinical implications. *Int J Geriatr Psychiatry* 2009; 24: 509–517.
25. Arlt S, Lindner R, Rosler A, et al. Adherence to medication in patients with dementia: predictors and strategies for improvement. *Drugs Aging* 2008; 25: 1033–1047.
26. Sabayan B, Wijnsman LW, Foster-Dingley JC, et al. Association of visit-to-visit variability in blood pressure with cognitive function in old age: prospective cohort study. *BMJ* 2013; 347: f4600.
27. Beevers G, Lip GYH and O'Brien E. Blood pressure measurement: Part II – Conventional sphygmomanometry: technique of auscultatory blood pressure measurement. *BMJ* 2001; 322: 1043–1047.
28. Roerecke M, Kaczorowski J and Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. *JAMA Intern Med*. Epub ahead of print 5 February 2019. DOI: 10.1001/jamainternmed.2018.6551.
29. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. *Alzheimer’s Dementia: the journal of the Alzheimer’s Association* 2014; 10: 844–852.
30. Hessen E, Eckerström M, Nordlund A, et al. Subjective cognitive impairment is a predominantly benign condition in memory clinic patients followed for 6 years: the Gothenburg–Oslo MCI Study. *Dementia Geriatric Cognit Disord EXTRA* 2017; 7: 1–14.